Evidence map›Paper›PMID 28013261›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017

Increased Antiviral Treatment Among Hospitalized Children and Adults With Laboratory-Confirmed Influenza, 2010-2015.

Grace D Appiah, Sandra S Chaves, Pam D Kirley, Lisa Miller, James Meek, Evan Anderson, Oluwakemi Oni, Patricia Ryan, Seth Eckel, Ruth Lynfield and 13 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Oseltamivir Treatment of Influenza in Children.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 16 institutions in 1 country.

Grace D AppiahEpidemic Intelligence Service and Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia; ydg3@cdc.gov.
Sandra S ChavesEpidemic Intelligence Service and Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Pam D KirleyCalifornia Emerging Infections Program, Oakland.
Lisa MillerColorado Department of Public Health and Environment, Denver.
James MeekConnecticut Emerging Infections Program, Yale School of Public Health, New Haven.
Evan AndersonDepartments of Pediatrics and Medicine, Emory University School of Medicine, and Atlanta Veterans Affairs Medical Center, Atlanta, Georgia.
Oluwakemi OniIowa Department of Health, Des Moines.
Patricia RyanMaryland Department of Health and Mental Hygiene, Baltimore.
Seth EckelMichigan Department of Health and Human Services, Lansing.
Ruth LynfieldMinnesota Department of Health, St Paul.
Marisa BargstenNew Mexico Department of Health, Santa Fe.
Shelley M ZanskyNew York State Department of Health, Albany; University of Rochester School of Medicine and Dentistry, Rochester, New York.
Nancy BennettEpidemic Intelligence Service and Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Krista LungOhio Department of Health, Columbus.
Christie McDonald-HammOklahoma Department of Health, Oklahoma City.
Ann ThomasOregon Department of Public Health, Portland.
Diane BradyRhode Island Department of Health, Providence.
Mary L LindegrenVanderbilt University School of Medicine, Nashville, Tennessee; and.
William SchaffnerVanderbilt University School of Medicine, Nashville, Tennessee; and.
Mary HillUtah Department of Health, Salt Lake City.
Shikha GargEpidemic Intelligence Service and Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Alicia M FryEpidemic Intelligence Service and Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Angela P CampbellEpidemic Intelligence Service and Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia; ydg3@cdc.gov app4@cdc.gov.
Centers for Disease Control and Prevention · USVanderbilt University · USColorado Department of Public Health and Environment · USEmory University · USEpidemic Intelligence Service · USIbis Reproductive Health · USIowa Department of Public Health · USMaryland Department of Health · USMichigan Department of Health and Human Services · USMinnesota Department of Health · USNew Mexico Department of Health · USNew York State Department of Health · USOhio Department of Health · USRhode Island Department of Health · USUniversity of Rochester · USUtah Department of Health · US

Funding

Intramural CDC HHS CC999999NCHM CDC HHS U38 HM000414
6 · The paper itself

Abstract

(See the Editorial Commentary by Martin on pages 368-9.)Using population-based surveillance data, we analyzed antiviral treatment among hospitalized patients with laboratory-confirmed influenza. Treatment increased after the influenza A(H1N1) 2009 pandemic from 72% in 2010-2011 to 89% in 2014-2015 (P < .001). Overall, treatment was higher in adults (86%) than in children (72%); only 56% of cases received antivirals on the day of admission.

Indexed as

Influenza A Virus, H1N1 SubtypeAdolescentAdultAgedAntiviral AgentsChildChild, PreschoolCohort StudiesFemaleHumansInfantInfant, NewbornInfluenza, HumanLength of StayLongitudinal StudiesMaleAntiviral AgentsOseltamivirantiviralinfluenzaoseltamivir.

Identifiers

PMID28013261
PMCPMC5480237
OpenAlexW2555921202

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.